CN Patent

CN116075592A — 用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2023-05-05 · 3y expired

What this patent protects

本发明涉及靶向GPAM基因的双链核糖核酸(dsRNA)组合物，以及抑制GPAM表达的方法，和使用这类dsRNA组合物治疗受益于GPAM表达降低的受试者(例如患有GPAM相关疾病、障碍或病症的受试者)的方法。

USPTO Abstract

本发明涉及靶向GPAM基因的双链核糖核酸(dsRNA)组合物，以及抑制GPAM表达的方法，和使用这类dsRNA组合物治疗受益于GPAM表达降低的受试者(例如患有GPAM相关疾病、障碍或病症的受试者)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116075592A
Jurisdiction
CN
Classification
—
Expires
2023-05-05
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.